NCT06096779

A PHASE II, OPEN-LABEL, MULTI-COHORT, MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS.

This is a Phase II research study that is designed to investigate the effectiveness and safety of a treatment in a specific group of patients. The study is specifically targeting patients who have liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable). These patients also have cirrhosis of the liver classified as Child-Pugh B7 or B8. Child-Pugh scoring is used to assess the severity of liver cirrhosis, with B7 and B8 indicating moderate to severe impairment of liver function. The main goal of this study is to evaluate how well the treatment works in these patients with advanced liver cancer and impaired liver function, while also assessing its safety profile. The treatment being tested could be a new drug, a combination of drugs, or a different therapeutic approach aimed at improving outcomes for this specific group of patients.

Phase II: An advanced point of testing, where they're trying to confirm if a treatment works well.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06096779

Clinical Trial Site: Einstein

To see all available clinical trials click here.